[Clinical indications for PET in oncology]

Area of Science:

• Oncology
• Nuclear Medicine
• Medical Imaging

Background:

• Positron Emission Tomography (PET) leverages the increased glucose metabolism characteristic of tumor tissues for diagnostic purposes.
• Its efficacy has been established across numerous cancer types in substantial patient cohorts.

Purpose of the Study:

• To elucidate the diagnostic utility of PET in oncology.
• To highlight PET's role in differentiating tumor recurrence from fibrosis and identifying lymph node metastasis.
• To explore PET's application in treatment selection and monitoring.

Main Methods:

• Utilizing the principle of elevated glucose metabolism in malignant tissues for detection.
• Conducting validity studies in various cancers including colorectal, pulmonary, hepatic, musculoskeletal, and lymphomas.
• Measuring chemotherapeutic agent uptake and hormone receptor presence prior to treatment initiation.

Main Results:

• PET effectively differentiates residual tumor or recurrence from fibrosis.
• It distinguishes lymph node metastasis from other adenopathies, regardless of size.
• PET is valuable in staging decisions, particularly concerning tumor operability.
• Pre-treatment measurements of drug uptake and receptor status allow for therapy optimization.
• Monitoring therapeutic response and detecting resistance development is feasible with PET.

Conclusions:

• PET imaging is a valuable tool in oncology for diagnosis, staging, and treatment monitoring.
• It enables personalized therapy selection by predicting treatment response and identifying resistance.
• PET imaging improves patient outcomes by optimizing treatment strategies and minimizing adverse effects.